Health services utilization and cost of retinitis pigmentosa

Archives of Ophthalmology

Volumn 130, Issue 5, 2012, Pages 629-634

  Frick, Kevin D ^a   Roebuck, M Christopher ^b   Feldstein, Joshua I ^c   McCarty, Catherine A ^d   Grover, Lori L ^e  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^c Center for Applied Value Analysis Inc   (United States)

^d ESSENTIA INSTITUTE OF RURAL HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PLAN EMPLOYER DATA AND INFORMATION SET; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INFANT; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT CARE; PHYSICIAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; RETROSPECTIVE STUDY; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH SERVICES; HEALTH SERVICES RESEARCH; HUMANS; INFANT; INSURANCE, HEALTH; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; RETINITIS PIGMENTOSA; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84860898819     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.2820     Document Type: Article

References (52)

1. den Hollander AI, Black A, Bennett J, Cremers FP. Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest. 2010;120(9):3042-3053.
2. Guide Dogs for the Blind Association. The costs of blindness: an analysis of the costs of visual impairment and blindness in the United Kingdom. http://www.healthyeyes.org.uk/index.php?id=25&type=33. Accessed June 26, 2011.
3. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795-1809. (Pubitemid 44739028)
4. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;1:40.
5. Berson EL. Long-term visual prognoses in patients with retinitis pigmentosa: the Ludwig von Sallmann lecture. Exp Eye Res. 2007;85(1):7-14. (Pubitemid 47017263)
6. Grover S, Fishman GA, Anderson RJ, Alexander KR, Derlacki DJ. Rate of visual field loss in retinitis pigmentosa. Ophthalmology. 1997;104(3):460-465. (Pubitemid 27120301)
7. Berson EL, Sandberg MA, Rosner B, Birch DG, Hanson AH. Natural course of retinitis pigmentosa over a three-year interval. Am J Ophthalmol. 1985;99(3):240-251. (Pubitemid 15143427)
8. Birch DG, Anderson JL, Fish GE. Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod dystrophy. Ophthalmology. 1999;106(2):258-268. (Pubitemid 30191621)
9. Massof R, Dagnelie G, Benzschawel T, Palmer R, Finkelstein D. First order dynamics of visual field loss in retinitis pigmentosa. Clin Vis Sci. 1990;5(1):1-26.
10. American Optometric Association. Optometric Clinical Practice Guideline: Care of the Patient With Visual Impairment Low Vision Rehabilitation. St Louis, MO: American Optometric Association; 2007.
11. Musarella MA, Macdonald IM. Current concepts in the treatment of retinitis pigmentosa. J Ophthalmol. 2011;2011:753547.
12. Cideciyan AV. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res. 2010;29(5):398-427.
13. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2231-2239. (Pubitemid 351724452)
14. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther. 2009;20(9):999-1004.
15. Caspi A, Dorn JD, McClure KH, Humayun MS, Greenberg RJ, McMahon MJ. Feasibility study of a retinal prosthesis: spatial vision with a 16-electrode implant. Arch Ophthalmol. 2009;127(4):398-401.
16. Zrenner E, Bartz-Schmidt KU, Benav H, et al. Subretinal electronic chips allow blind patients to read letters and combine them to words. Proc Biol Sci. 2011;278(1711):1489-1497.
17. Radtke ND, Aramant RB, Petry HM, Green PT, Pidwell DJ, Seiler MJ. Vision improvement in retinal degeneration patients by implantation of retina together with retinal pigment epithelium. Am J Ophthalmol. 2008;146(2):172-182.
18. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A. 2006;103(10):3896-3901. (Pubitemid 43376652)
19. Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi R. Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats. Invest Ophthalmol Vis Sci. 2010;51(8):4243-4252.
20. Herse P. Retinitis pigmentosa: visual function and multidisciplinary management. Clin Exp Optom. 2005;88(5):335-350.
21. Ivers RQ, Cumming RG, Mitchell P, Simpson JM, Peduto AJ. Visual risk factors for hip fracture in older people. J Am Geriatr Soc. 2003;51(3):356-363. (Pubitemid 36348897)
22. Vu HT, Keeffe JE, McCarty CA, Taylor HR. Impact of unilateral and bilateral vision loss on quality of life. Br J Ophthalmol. 2005;89(3):360-363. (Pubitemid 40327623)
23. Spencer C, Frick K, Gower EW, Kempen JH, Wolff JL. Disparities in access to medical care for individuals with vision impairment. Ophthalmic Epidemiol. 2009;16(5):281-288.
24. Brézin AP, Lafuma A, Fagnani F, Mesbah M, Berdeaux G. Blindness, low vision, and other handicaps as risk factors attached to institutional residence. Br J Ophthalmol. 2004;88(10):1330-1337. (Pubitemid 39312982)
25. Javitt JC, Zhou Z, Willke RJ. Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss. Ophthalmology. 2007;114(2):238-245.
26. Koenes SG, Karshmer JF. Depression: a comparison study between blind and sighted adolescents. Issues Ment Health Nurs. 2000;21(3):269-279.
27. Lin MY, Gutierrez PR, Stone KL, et al Study of Osteoporotic Fractures Research Group. Vision impairment and combined vision and hearing impairment predict cognitive and functional decline in older women. J Am Geriatr Soc. 2004;52(12):1996-2002. (Pubitemid 41725014)
28. Heckenlively JR, Yoser SL, Friedman LH, Oversier JJ. Clinical findings andcommon symptoms in retinitis pigmentosa. Am J Ophthalmol. 1988;105(5):504-511.
29. Gordo MA, Recio J, Sánchez-Barceló EJ. Decreased sleep quality in patients suffering from retinitis pigmentosa. J Sleep Res. 2001;10(2):159-164. (Pubitemid 32525686)
30. Szlyk JP, Fishman GA, Alexander KR, Revelins BI, Derlacki DJ, Anderson RJ. Relationship between difficulty in performing daily activities and clinical measures of visual function in patients with retinitis pigmentosa. Arch Ophthalmol. 1997;115(1):53-59. (Pubitemid 27034931)
31. Hahm BJ, Shin YW, Shim EJ, et al. Depression and the vision-related quality of life in patients with retinitis pigmentosa. Br J Ophthalmol. 2008;92(5):650-654.
32. Jangra D, Ganesh A, Thackray R, et al. Psychosocial adjustment to visual loss in patients with retinitis pigmentosa. Ophthalmic Genet. 2007;28(1):25-30. (Pubitemid 46555533)
33. Rüther K, Banhart F, Kremmer S, Apfelstedt-Sylla E, Zrenner E. Social ophthalmologic aspects of retinitis pigmentosa [in German]. Ophthalmologe. 1995;92(5):704-707.
34. Steinmetz E; US Census Bureau. Americans with disabilities: 2002. Household economic studies. 2006. Current Populations Reports P70-107. http://www.census.gov/prod/2006pubs/p70-107.pdf. Accessed June 26, 2011.
35. Prevent Blindness America. The economic impact of vision problems: the toll of major adult eye disorders, visual impairment and blindness on the U.S. economy. http://www.preventblindness.net/site/DocServer/Impact-of-Vision- Problems.pdf?docID=1321. Accessed June 26, 2011; 2007.
36. Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol. 2007;125(4):544-550. (Pubitemid 46596727)
37. Hansen L, Chang S. Health Research Data for the Real World: The Thomson Reuters Market Scan Databases. Ann Arbor, MI: Thomson Reuters; 2010.
38. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
39. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
40. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. (Pubitemid 41587600)
41. Healthcare Cost and Utilization Project (HCUP). Clinical Classifications Software (CCS) for ICD-9-CM : Agency for Healthcare Research and Quality Web site. http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp. Updated May 2011. Accessed June 28, 2011.
42. Elixhauser A, Steiner C, Whittington C, McCarthy E. Clinical classifications for health policy research: hospital inpatient statistics, 1995. HCUP-3 Research Note. Agency for Health Care Policy and Research; 1998. AHCPR publication 98-0049. http://www.ahrq.gov/data/his95/clinclas.htm. Accessed June 28, 2011.
43. McCarty CA, Nanjan MB, Taylor HR. Vision impairment predicts 5 year mortality. Br J Ophthalmol. 2001;85(3):322-326. (Pubitemid 32250763)
44. Hayeems RZ, Geller G, Finkelstein D, Faden RR. How patients experience progressive loss of visual function: a model of adjustment using qualitative methods. Br J Ophthalmol. 2005;89(5):615-620. (Pubitemid 40569722)
45. Kruskal W, Wallis W. Use of ranks in one-criterion variance analysis. J Am Statist Assn. 1952;47(260):583-621.
46. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461-494. (Pubitemid 32515166)
47. STATA Release 11.1 [computer program]. College Station, TX: StataCorp LP; 2009.
48. Frick KD, Walt JG, Chiang TH, et al. Direct costs of blindness experienced by patients enrolled in managed care. Ophthalmology. 2008;115(1):11-17. (Pubitemid 350309399)
49. Keeffe JE, Chou SL, Lamoureux EL. The cost of care for people with impaired vision in Australia. Arch Ophthalmol. 2009;127(10):1377-1381.
50. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754-1760. (Pubitemid 44920172)
51. Wirth KE, Rein DB. The economic costs and benefits of dog guides for the blind. Ophthalmic Epidemiol. 2008;15(2):92-98. (Pubitemid 351574437)
52. Wong EY, Chou SL, Lamoureux EL, Keeffe JE. Personal costs of visual impairment by different eye diseases and severity of visual loss. Ophthalmic Epidemiol. 2008;15(5):339-344.